← All trials
NCT06260462
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2012
- Primary completion
- Sep 30, 2022
- Completion date
- Dec 30, 2023
- First posted
- Feb 15, 2024
- Last posted
- Feb 15, 2024
- Enrollment
- 88
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PalermoLead sponsor
- University of PalermoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.